The Extracorporeal Membrane Oxygenation Market is estimated to be valued at USD 535.4 million in 2025 and is projected to reach USD 719.6 million by 2035, registering a compound annual growth rate (CAGR) of 3.0% over the forecast period. The extracorporeal membrane oxygenation (ECMO) market is projected to experience consistent growth, increasing from USD 461.9 million in 2020 to approximately USD 719.6 million by 2035, marking a significant expansion over the 16-year period. From 2020 to 2030, the market value advances from USD 461.9 million to USD 602.6 million, driven by the rising prevalence of respiratory and cardiac diseases, greater adoption of ECMO technology in critical care settings, and heightened awareness among healthcare providers regarding its therapeutic benefits.
Technological innovations in ECMO systems, including enhanced oxygenators, portable and compact devices, and improved patient monitoring integration, support broader clinical use and market penetration. Increasing investments in healthcare infrastructure, especially across emerging economies, alongside favorable regulatory approvals and reimbursement policies, further propel market growth during this phase. Between 2031 and 2035, the market accelerates from USD 620.7 million to USD 719.6 million, fueled by advancements in ECMO therapy protocols, expanded indications beyond traditional applications, and growing clinical evidence endorsing its efficacy and safety.
The integration of telemedicine and remote monitoring technologies enables more effective patient management, while the rising focus on personalized medicine stimulates innovation in ECMO treatments. The increasing aging population and the prevalence of chronic conditions that require advanced respiratory and cardiac support contribute to sustained demand. The ECMO market is positioned for robust and steady growth through 2035, underpinned by continuous technological progress, expanding clinical utilization, and improving access to advanced healthcare services globally.
| Metric | Value |
|---|---|
| Extracorporeal Membrane Oxygenation Market Estimated Value in (2025 E) | USD 535.4 million |
| Extracorporeal Membrane Oxygenation Market Forecast Value in (2035 F) | USD 719.6 million |
| Forecast CAGR (2025 to 2035) | 3.0% |
Hospitals and intensive care units are increasingly adopting ECMO systems due to improved survival outcomes in severe respiratory or cardiac failure cases. Demand is further reinforced by the aging population, increasing prevalence of chronic heart and lung diseases, and expansion of extracorporeal life support (ECLS) programs in both developed and emerging healthcare systems. Technological innovation in portable ECMO configurations, automation of oxygenation monitoring, and growing clinical training programs are creating a stronger ecosystem for patient management.
Additionally, post-pandemic critical care reforms and expanded applications in extracorporeal cardiopulmonary resuscitation (ECPR) are expected to accelerate global ECMO deployment across a broader range of clinical settings.
The extracorporeal membrane oxygenation market is segmented by modality, application, patient population, and geographic regions. The extracorporeal membrane oxygenation market is divided into Veno-arterial, Veno-venous, and Arterio-venous. In terms of application, the extracorporeal membrane oxygenation market is classified into Cardiac, Respiratory, and Extracorporeal cardiopulmonary resuscitation (ECPR).
The patient population of the extracorporeal membrane oxygenation market is segmented into Adult, Infant, and Pediatric. Regionally, the extracorporeal membrane oxygenation industry is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.
The venoarterial (VA) modality is projected to account for 47.80% of the ECMO market share in 2025, making it the dominant modality in clinical usage. This leadership is driven by its dual function of providing both cardiac and respiratory support, which is essential in treating patients with cardiogenic shock, cardiac arrest, or severe myocardial dysfunction.
VA-ECMO is increasingly being used in high-acuity environments such as cardiac ICUs and emergency settings due to its capacity to ensure hemodynamic stabilization while oxygenating the blood. The ability to rapidly reverse hypoperfusion and maintain organ perfusion during circulatory collapse has positioned it as a critical intervention in acute care pathways.
As hospitals enhance their emergency cardiac protocols and mobile ECMO retrieval teams become more common, the adoption of venoarterial systems continues to gain strong momentum.
Cardiac-related cases are expected to generate 42.10% of the total ECMO revenue by 2025, establishing this as the leading application area. The growth of this segment is supported by the rising incidence of acute heart failure, myocardial infarctions, and refractory cardiac arrests.
ECMO has emerged as a vital life-sustaining technology for bridging patients to recovery, transplantation, or long-term mechanical circulatory support. Increasing clinical evidence supporting its efficacy in post-cardiotomy syndrome and cardiogenic shock has led to broader institutional protocols adopting ECMO in cardiac cases.
Further support from cardiovascular societies and inclusion in advanced cardiac life support (ACLS) recommendations are enhancing clinical integration. As cardiac care centers focus on rapid-response systems and intensive post-operative care, ECMO utilization in cardiac settings is expected to maintain its strong trajectory.
The adult patient population is anticipated to contribute 56.40% of total ECMO usage by 2025, making it the largest demographic segment. This leadership is attributed to the high prevalence of chronic cardiac and respiratory conditions in adults, including COPD, acute respiratory distress syndrome (ARDS), and ischemic heart disease.
The pandemic further underscored the role of ECMO in adult populations, especially for severe respiratory failure, where conventional ventilation proved insufficient. Increasing ICU capacity, improved access to tertiary care, and growing investment in ECMO training and simulation programs for adult care have expanded its usage.
Moreover, ongoing innovation in adult-compatible cannulation techniques and compact circuit designs is enhancing patient outcomes and operational efficiency. With rising critical care demand and a maturing adult ECMO ecosystem, this demographic segment is expected to retain its dominance in the near term.
The ECMO market is expanding due to growing demand for life support, especially in critical and pediatric care. Increased healthcare investment and improved patient outcomes are further driving the adoption of ECMO devices worldwide.
The demand for extracorporeal membrane oxygenation (ECMO) systems is rising due to the increasing prevalence of cardiovascular diseases and respiratory failure. As these conditions become more common, particularly in aging populations, the need for life-saving technologies that offer prolonged cardiac and respiratory support grows. ECMO is particularly crucial in critical care scenarios, providing temporary support to patients who cannot survive on conventional methods. Hospitals and healthcare facilities are investing in ECMO technology to enhance their ability to manage high-risk patients and offer better chances of survival, driving market growth.
Pediatric and neonatal ECMO applications have gained significant traction in recent years. Advances in ECMO technology have allowed for the development of smaller, more versatile systems suitable for infants and children with severe heart or lung failure. This shift is fueled by the rising survival rates in pediatric intensive care units (PICUs), where ECMO offers critical support during emergency procedures or after surgery. Neonatal ECMO, particularly in premature infants, is becoming more common as a life-saving intervention. These expanding applications are fueling market demand for ECMO devices, with healthcare providers aiming to improve pediatric outcomes.
Healthcare investments in critical care units are increasing to meet the growing demand for advanced life-support technologies. As hospitals and specialized care centers expand, there is a focus on integrating ECMO into their intensive care protocols. Government initiatives, along with private-sector healthcare investments, are promoting the adoption of ECMO in hospitals worldwide. These investments are not only improving patient outcomes but also enhancing the infrastructure necessary to support high-cost, high-tech devices like ECMO. A more robust healthcare system, with improved ICU capabilities, is driving growth in the ECMO market, making it an essential component of critical care.
With increasing clinical experience and better management protocols, ECMO devices are now seen as a crucial part of patient management for life-threatening conditions. ECMO’s use is expanding beyond emergency care, with long-term survival rates for patients improving due to more sophisticated management techniques and the integration of ECMO in planned surgeries. Medical teams are now better trained, and there is greater knowledge around when and how to implement ECMO to maximize its benefits. These improvements in patient management are further driving ECMO adoption in hospitals globally, enhancing both survival rates and post-care recovery.
The extracorporeal membrane oxygenation (ECMO) market is projected to grow globally at a CAGR of 3.0% from 2025 to 2035, driven by increasing prevalence of heart and lung diseases, advancements in ECMO technology, and growing awareness about its clinical benefits in critical care. China leads with a CAGR of 4.1%, supported by the rapid expansion of healthcare infrastructure, increasing cardiovascular diseases, and growing demand for advanced life support systems. India follows with a CAGR of 3.8%, fueled by rising healthcare investments, a growing patient population, and greater adoption of ECMO in critical care units.
France grows at 3.2%, with the rise in cardiovascular surgeries, increasing hospital investments, and adoption of advanced ECMO systems. The United Kingdom achieves a CAGR of 2.9%, driven by technological advancements in ECMO systems and their growing use in critical care settings. The United States records a CAGR of 2.6%, influenced by steady demand from hospitals and medical centers, along with continuous innovations in ECMO technology. This growth trajectory highlights the increasing significance of ECMO technology in critical care, with rising healthcare demands and advancements in medical treatments driving growth in both developed and emerging markets.
The UK’s ECMO market grew at a CAGR of 2.4% from 2020 to 2024 and is projected to rise to 2.9% during 2025-2035. The earlier growth was steady but moderate, as ECMO technology is primarily used in specialized critical care settings such as cardiac and respiratory failure. However, the market is expected to see a slight acceleration in the coming decade, driven by advancements in ECMO systems, a growing aging population, and increasing prevalence of cardiovascular diseases. Improvements in healthcare infrastructure and technology adoption will contribute to higher ECMO use. The integration of more user-friendly, efficient, and portable ECMO devices will further support market growth as hospitals and healthcare facilities focus on better patient outcomes.
China is projected to grow at a CAGR of 4.1% in the ECMO market during 2025-2035, surpassing the global average of 3.0%. From 2020 to 2024, the market grew at a CAGR of 3.5%, driven by increasing healthcare infrastructure investments, a rising number of cardiovascular and respiratory diseases, and the growing adoption of advanced medical technologies. The acceleration in the upcoming decade is expected to be fueled by the Chinese government’s focus on improving healthcare services, particularly in critical care and life-support systems like ECMO. As the country faces an increasing burden of chronic diseases and aging populations, the demand for ECMO technology will continue to rise, along with the development of more efficient and affordable devices.
India’s ECMO market is expected to grow at a CAGR of 3.8% from 2025 to 2035, slightly above the global average of 3.0%. The market grew at a CAGR of 3.2% from 2020 to 2024, supported by the country’s expanding healthcare sector, rising incidences of chronic diseases, and growing adoption of ECMO in major healthcare centers. The acceleration in demand for ECMO devices in the next decade will be driven by rising healthcare investments, improvements in medical infrastructure, and greater awareness of advanced life-support systems. Additionally, as India’s healthcare system embraces more high-tech, critical care solutions, ECMO technology will see broader adoption, particularly in tier-1 and tier-2 cities.
France’s ECMO market is expected to grow at a CAGR of 3.2% during 2025-2035. The market grew at a CAGR of 2.8% from 2020 to 2024, driven by strong demand from critical care units, particularly in heart and lung failure treatments. The market will likely see increased growth due to technological advancements in ECMO devices, making them more accessible and easier to use in hospitals. France’s healthcare system’s focus on improving patient outcomes, particularly for cardiovascular patients, will further drive demand for ECMO. The aging population and increasing incidence of respiratory and cardiovascular diseases will contribute to growing ECMO adoption.
The USA ECMO market is projected to grow at a CAGR of 2.6% from 2025 to 2035. The market grew at a CAGR of 2.1% from 2020 to 2024, driven by demand in high-end hospitals and healthcare institutions. The growth is expected to accelerate as ECMO technology continues to improve, offering better portability, efficiency, and patient care capabilities. The USA market will also be boosted by the rising incidence of cardiovascular diseases, respiratory disorders, and other conditions requiring advanced life support. Healthcare investments and expanding ECMO applications in the treatment of various diseases will drive further market demand.
The extracorporeal membrane oxygenation (ECMO) market is characterized by strong competition among global medical device manufacturers, each focusing on technological advancements, patient safety, and integration with hospital systems. Getinge AB leads with a wide range of ECMO systems, offering both centralized and mobile solutions, emphasizing reliability, ease of use, and efficient oxygenation for critical care. Abbott Laboratories specializes in advanced cardiovascular technologies and integrated ECMO solutions, with a focus on improving patient outcomes through real-time monitoring and precision control.
Fresenius Medical Care AG & Co. KGaA offers comprehensive ECMO systems with enhanced connectivity and automation, catering to high-demand clinical environments. Braile Biomedica is recognized for providing innovative ECMO pumps and oxygenators, particularly targeting emerging markets with cost-effective solutions. Edwards Lifesciences Corporation focuses on heart-lung support technologies, enhancing ECMO functionality in critical cardiovascular interventions. Abiomed is known for its cutting-edge heart pump solutions, complementing ECMO for patients with severe cardiac failure.
Eurosets offers customized ECMO systems designed to integrate with patient-specific needs, catering to diverse clinical settings. LivaNova PLC specializes in offering advanced oxygenator technologies with enhanced gas exchange capabilities for optimal respiratory support. Medtronic brings its expertise in medical device innovation with ECMO systems that emphasize patient safety and user-friendly interfaces.
MicroPort Scientific Corporation and Nipro also contribute with high-quality ECMO solutions, focusing on cost-effectiveness and adaptability to various healthcare needs. SB-Kawasumi Laboratories Inc. offers reliable blood oxygenators for ECMO systems, ensuring safe and efficient patient management. Spectrum Medical delivers high-performance ECMO circuits and accessories, enhancing clinical outcomes through precision engineering. Terumo Corporation's ECMO solutions cater to specialized needs with a focus on blood pumps, oxygenators, and integrated patient care systems.
Companies are focusing on developing mobile ECMO units that can be used in ambulances or emergency medical transport. This has been particularly useful in critical situations like cardiac arrest or severe respiratory failure, where rapid intervention is essential. A leading player in the ECMO market, Getinge offers a range of ECMO machines, including the CardioHelp system, which is widely used in critical care settings. The company continues to innovate with portable and user-friendly ECMO devices.
| Item | Value |
|---|---|
| Quantitative Units | USD 535.4 Million |
| Modality | Venoarterial, Veno-venous, and Arterio-venous |
| Application | Cardiac, Respiratory, and Extracorporeal cardiopulmonary resuscitation (ECPR) |
| Patient Population | Adult, Infant, and Pediatric |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
| Country Covered | United States, Canada, Germany, France, United Kingdom, China, Japan, India, Brazil, South Africa |
| Key Companies Profiled | Getinge AB, Abbott Laboratories, Fresenius Medical Care AG & Co, KGaA, Braile Biomedica, Edwards Lifesciences Corporation, Abiomed, Eurosets, LivaNova PLC, Medtronic, MicroPort Scientific Corporation, Nipro, SB-Kawasumi Laboratories Inc, Spectrum Medical, and Terumo Corporation |
| Additional Attributes | Dollar sales projections, and growth trends by region. Key insights would include market share by application (e.g., adult, pediatric), customer preferences, and competitive landscape. They would also seek data on pricing trends, regulatory impacts and driving demand. |
The global extracorporeal membrane oxygenation market is estimated to be valued at USD 535.4 million in 2025.
The market size for the extracorporeal membrane oxygenation market is projected to reach USD 719.6 million by 2035.
The extracorporeal membrane oxygenation market is expected to grow at a 3.0% CAGR between 2025 and 2035.
The key product types in extracorporeal membrane oxygenation market are venoarterial, veno-venous and arterio-venous.
In terms of application, cardiac segment to command 42.1% share in the extracorporeal membrane oxygenation market in 2025.
Explore Similar Insights
Extracorporeal Membrane Oxygenation Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
